GSK said it remains confident in its ability to absorb the financial impact of potential US pharmaceutical tariffs as it ...

GSK plc GSK reported first-quarter 2025 core earnings of $1.13 per American depositary share (ADS), which beat the Zacks ...

KEY TAKEAWAYS U.S.-listed shares of GSK are gaining in premarket trading Wednesday after the British pharma giant posted ...

GSK (LSE:GSK) reported a significant improvement in its first-quarter earnings, with sales, net income, and earnings per ...

GSK (GSK) stock gains as the company's Q1 2025 results beat Street forecasts thanks to its Specialty Medicines business. Read ...

GSK will use technologies including artificial intelligence to improve its productivity as a means of compensating for the potential financial hit from US tariffs on the pharmaceutical sector.

In its update, GSK reported a 17% rise in specialty medicines across its HIV, cancer, and respiratory business to £2.93 ...

As GSK weathers the storm of sinking vaccine sales and gears up for key launches in its specialty medicines sector, the ...

GSK reiterated shrugged off the potential impact of tariffs on Wednesday and reiterated its full-year outlook, following a ...

GSK’s dealmaking will be “cautious and disciplined” under the current trade war, but the pharma will focus on looking for ...

GSK posted adjusted earnings per share of $1.20, surpassing the consensus estimate of $1.02. Revenue for the quarter came in at $10.06 billion, beating expectations of $9.48 billion and representing a ...